Press-release for stocks published on this month

Prices are updated after-hours

therapeutics published : This month

save search

Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update
Published: 2024-04-18 (Crawled : 05:00) - globenewswire.com
ADXN | $22.8 0.89% 0.88% 16K

Health Technology

| Email alert Add to watchlist
year update therapeutics financial results

Pulmonary Embolism Therapeutics Market size to grow at a CAGR of 9.52% from 2022 to 2027, Technavio
Published: 2024-04-17 (Crawled : 00:00) - prnewswire.com
ABBV | $164.25 1.05% -0.76% 4M

Health Technology

| Email alert Add to watchlist
AMGN | $264.07 -0.59% -0.59% 2.2M

Health Technology

| Email alert Add to watchlist
therapeutics market

DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke
Published: 2024-04-17 (Crawled : 22:00) - biospace.com/
DMAC | News | $2.58 8.86% 8.14% 41K

Health Technology

| 4.43% | O: 4.43% H: 0.0% C: 0.0%
dm199 first stroke treatment for trial therapeutics

Viking Therapeutics to Report Financial Results for First Quarter 2024 on April 24, 2024
Published: 2024-04-17 (Crawled : 20:00) - prnewswire.com
LGND | News | $78.93 -1.24% -1.25% 180K

Health Technology

| Email alert Add to watchlist
VKTX | News | $66.53 -2.09% -2.13% 2M

Health Technology

| Email alert Add to watchlist
first report for therapeutics financial results

Poseida Therapeutics Hosts Gene Therapy R&D Day Highlighting New Scientific Advancements and Pipeline Focus
Published: 2024-04-17 (Crawled : 15:00) - biospace.com/
PSTX | News | $2.03 0.0% 980K

Health Technology

| 0.49% | O: 0.0% H: 2.46% C: 0.49%
day pipeline therapeutics therapy

Ventus Therapeutics Announces Results from Phase 1 Clinical Trial of VENT-02, a Novel, Orally Administered, Brain-Penetrant NLRP3 Inhibitor
Published: 2024-04-17 (Crawled : 14:00) - biospace.com/
NVO | News | $124.53 0.88% 0.0% 2.6M

Health Technology

| 0.87% | O: 1.22% H: 0.21% C: -0.34%
vent-02 trial therapeutics results

Biopharma Layoff Tracker 2024: Fujifilm, Genentech, Sanofi and More Cut Staff
Published: 2024-04-17 (Crawled : 14:00) - biospace.com/
SNYNF | News | $92.116 -2.18% 2.3K

Health Technology

| 0.63% | O: 0.12% H: 0.51% C: 0.51%
RLYB | News | $1.74 -3.33% -3.45% 520K

| -4.44% | O: -4.44% H: 0.0% C: 0.0%
JNJ | News | $144.77 0.22% -0.01% 9.3M

Health Technology

| -0.2% | O: -0.04% H: 0.28% C: -0.16%
VXRT | News | $0.8675 -3.01% -3.1% 1.1M

Health Technology

| -2.73% | O: -0.49% H: 2.25% C: -2.25%
TXMD | News | $1.88 -1.05% -1.06% 29K

Health Technology

| -0.53% | O: 2.63% H: 3.59% C: -3.08%
SNY | News | $46.125 0.71% 0.7% 3.7M

Health Technology

| 0.52% | O: 1.0% H: 0.19% C: -0.47%
PTCT | News | $25.19 -0.4% -0.4% 670K

Health Technology

| -0.51% | O: 0.83% H: 0.0% C: -1.33%
NKTR | News | $1.345 -9.73% -10.78% 3.3M

Health Technology

| -9.4% | O: -0.67% H: 1.35% C: -8.78%
MOR | News | $18.03 0.45% 0.44% 400K

Health Technology

| 0.5% | O: 0.17% H: 0.39% C: 0.33%
GLPG | News | $29.25 -0.81% -0.82% 190K

Health Technology

| -0.92% | O: -0.14% H: 0.17% C: -0.78%
AMRN | News | $0.9249 3.24% 3.14% 880K

Health Technology

| 3.69% | O: 3.69% H: 0.0% C: 0.0%
GOOGL | News | $155.45 0.68% 0.68% 21M

Technology Services

| 0.93% | O: 1.03% H: 0.94% C: -0.1%
GOOG | News S | $156.88 0.56% 0.56% 16M

Technology Services

| 0.77% | O: 0.97% H: 0.95% C: -0.2%
OCX | News J | $2.75 4.89% 36K

Health Technology

| -5.82% | O: -0.36% H: 0.0% C: -5.47%
biopharma sanofi

G1 Therapeutics to Release First Quarter 2024 Financial Results and Provide Business Update on May 1, 2024
Published: 2024-04-17 (Crawled : 13:00) - globenewswire.com
GTHX | News | $4.28 4.9% 4.67% 690K

Health Technology

| 4.9% | O: 1.72% H: 4.82% C: 3.13%
first therapeutics financial results

Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)
Published: 2024-04-17 (Crawled : 13:00) - globenewswire.com
ALLR | News | $1.505 -10.42% -11.63% 1.1M

n/a

| -9.52% | O: -9.52% H: 0.0% C: 0.0%
nasdaq extension therapeutics

Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer
Published: 2024-04-17 (Crawled : 13:00) - biospace.com/
STOK | News | $11.75 -5.62% -5.96% 740K

Health Technology

| -5.86% | O: 0.48% H: 3.68% C: -6.31%
commercial therapeutics

Windtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business Updates
Published: 2024-04-17 (Crawled : 12:00) - globenewswire.com
WINT | News | $0.3903 -7.4% -7.99% 110K

Health Technology

| -4.17% | O: 0.62% H: 0.0% C: -4.76%
business key therapeutics financial results

Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria
Published: 2024-04-17 (Crawled : 12:00) - globenewswire.com
CLDX | News | $39.66 2.75% 2.67% 910K

Health Technology

| 0.23% | O: 0.23% H: 0.0% C: 0.0%
urticaria study

Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease
Published: 2024-04-17 (Crawled : 12:00) - biospace.com/
SAGE | News | $12.585 -19.48% -24.2% 4.3M

Health Technology

| -17.57% | O: -15.02% H: 3.55% C: -3.01%
sage-718 disease treatment topline parkinson’s therapeutics results study

TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering
Published: 2024-04-17 (Crawled : 05:00) - globenewswire.com
TCRX | News | $6.76 -5.19% -5.47% 1.6M

Professional, Scientific, and T...

| -9.15% | O: -2.15% H: 1.24% C: -7.15%
MS | News | $90.08 1.06% -0.28% 9.5M

Finance

| -0.14% | O: -0.14% H: 0.0% C: 0.0%
million offering therapeutics

Alterity Therapeutics Parkinson’s Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting
Published: 2024-04-17 (Crawled : 01:00) - alteritytherapeutics.com
ATHE | News | $1.98 -3.42% -3.54% 120K

Health Technology

| -14.29% | O: -14.29% H: 0.0% C: 0.0%
disease neurology system meeting parkinson’s therapeutics

Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316
Published: 2024-04-17 (Crawled : 00:00) - globenewswire.com
ACRV | News P | $10.34 9.19% 8.41% 290K

| 10.83% | O: 3.32% H: 8.82% C: 7.26%
acr-368 acr-2316 pipeline ongoing preclinical for therapeutics oncosignature

BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn
Published: 2024-04-16 (Crawled : 23:00) - prnewswire.com
SNYNF | News | $92.116 -2.18% 2.3K

Health Technology

| 0.63% | O: 0.12% H: 0.51% C: 0.51%
SNY | News | $46.125 0.71% 0.7% 3.7M

Health Technology

| 0.52% | O: 1.0% H: 0.19% C: -0.47%
management company cell nurown trial therapeutics

Nurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Published: 2024-04-16 (Crawled : 22:00) - globenewswire.com
NRIX | $14.1 -3.75% -3.9% 970K

Health Technology

| -3.89% | O: 3.07% H: 0.79% C: -6.75%
offering therapeutics

TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering
Published: 2024-04-16 (Crawled : 20:00) - globenewswire.com
TCRX | News | $6.76 -5.19% -5.47% 1.6M

Professional, Scientific, and T...